Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 11/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.50 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL625719 | 1.00 | PRCP (0.53) | PRCPCYP3A4CYP2C9CYP1A2KCNH2 | |
| SCHEMBL625717 | 1.00 | PRCP (0.53) | PRCPCYP3A4CYP2C9CYP1A2KCNH2 | |
| SCHEMBL204012 | 0.94 | PRCP (0.49) | PRCPCYP3A4CYP2C9CYP1A2KCNH2 | |
| SCHEMBL19339746 | 0.90 | ALDH1A1 (0.47) | PRCPCYP3A4CYP2C9CYP1A2KCNH2 | |
| SCHEMBL10092578 | 0.89 | PRCP (0.50) | PRCPCYP3A4CYP2C9CYP1A2KCNH2 | |
| SCHEMBL10092363 | 0.89 | PRCP (0.50) | PRCPCYP3A4CYP2C9CYP1A2KCNH2 | |
| SCHEMBL11910995 | 0.86 | CYP3A4 (0.60) | PRCPCYP3A4CYP2C9CYP1A2KCNH2 | |
| SCHEMBL753302 | 0.86 | CYP3A4 (0.60) | PRCPCYP3A4CYP2C9CYP1A2KCNH2 | |
| SCHEMBL2706110 | 0.85 | CYP3A4 (0.58) | PRCPCYP3A4CYP2C9CYP1A2KCNH2 | |
| SCHEMBL25638633 | 0.85 | PRCP (0.57) | PRCPCYP3A4CYP2C9CYP1A2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040977-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| EP-2398474-A1 | INHIBITORS OF HCV NS5A | Presidio Pharmaceuticals, Inc. (US) | 2011-12-28 | — | — | EP | disclosed |
| WO-2010096777-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2010-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040977-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | PRCP 298/4885CYP3A4 2538/4885CYP2C9 3984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.